152 related articles for article (PubMed ID: 20006519)
1. A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent.
Kong Y; Wang K; Edler MC; Hamel E; Mooberry SL; Paige MA; Brown ML
Bioorg Med Chem; 2010 Jan; 18(2):971-7. PubMed ID: 20006519
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
[TBL] [Abstract][Full Text] [Related]
3. A 2-step synthesis of Combretastatin A-4 and derivatives as potent tubulin assembly inhibitors.
Barnes NG; Parker AW; Ahmed Mal Ullah AA; Ragazzon PA; Hadfield JA
Bioorg Med Chem; 2020 Oct; 28(19):115684. PubMed ID: 32912434
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel combretastatin A-4 thio derivatives as microtubule targeting agents.
Stefański T; Mikstacka R; Kurczab R; Dutkiewicz Z; Kucińska M; Murias M; Zielińska-Przyjemska M; Cichocki M; Teubert A; Kaczmarek M; Hogendorf A; Sobiak S
Eur J Med Chem; 2018 Jan; 144():797-816. PubMed ID: 29291446
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel imidazole-chalcone derivatives as potential anticancer agents and tubulin polymerization inhibitors.
Rahimzadeh Oskuei S; Mirzaei S; Reza Jafari-Nik M; Hadizadeh F; Eisvand F; Mosaffa F; Ghodsi R
Bioorg Chem; 2021 Jul; 112():104904. PubMed ID: 33933802
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis and Antitumor Activity of Novel link-bridge and B-Ring Modified Combretastatin A-4 (CA-4) Analogues as Potent Antitubulin Agents.
Duan YT; Man RJ; Tang DJ; Yao YF; Tao XX; Yu C; Liang XY; Makawana JA; Zou MJ; Wang ZC; Zhu HL
Sci Rep; 2016 May; 6():25387. PubMed ID: 27138035
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of carbamates derived from aminocombretastatin A-4 as vascular disrupting agents.
Conesa-Milián L; Falomir E; Murga J; Carda M; Meyen E; Liekens S; Alberto Marco J
Eur J Med Chem; 2018 Mar; 147():183-193. PubMed ID: 29432949
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Multifunctional Hybrid Analogs for Stilbenes, Chalcones and Flavanones.
Cagir A; Odaci B; Varol M; Akcok I; Okur O; Koparal AT
Anticancer Agents Med Chem; 2018 Feb; 17(14):1915-1923. PubMed ID: 28554313
[TBL] [Abstract][Full Text] [Related]
9. Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.
Carr M; Greene LM; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
Eur J Med Chem; 2010 Dec; 45(12):5752-66. PubMed ID: 20933304
[TBL] [Abstract][Full Text] [Related]
10. 2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents.
Chang JY; Yang MF; Chang CY; Chen CM; Kuo CC; Liou JP
J Med Chem; 2006 Oct; 49(21):6412-5. PubMed ID: 17034147
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents.
Wang G; Li C; He L; Lei K; Wang F; Pu Y; Yang Z; Cao D; Ma L; Chen J; Sang Y; Liang X; Xiang M; Peng A; Wei Y; Chen L
Bioorg Med Chem; 2014 Apr; 22(7):2060-79. PubMed ID: 24629450
[TBL] [Abstract][Full Text] [Related]
12. Photoswitchable anticancer activity via trans-cis isomerization of a combretastatin A-4 analog.
Sheldon JE; Dcona MM; Lyons CE; Hackett JC; Hartman MC
Org Biomol Chem; 2016 Jan; 14(1):40-9. PubMed ID: 26503632
[TBL] [Abstract][Full Text] [Related]
13. 1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin.
Odlo K; Hentzen J; dit Chabert JF; Ducki S; Gani OA; Sylte I; Skrede M; Flørenes VA; Hansen TV
Bioorg Med Chem; 2008 May; 16(9):4829-38. PubMed ID: 18396050
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4.
Madadi NR; Penthala NR; Howk K; Ketkar A; Eoff RL; Borrelli MJ; Crooks PA
Eur J Med Chem; 2015 Oct; 103():123-32. PubMed ID: 26352674
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, biological evaluation and cocrystal structures with tubulin of chiral β-lactam bridged combretastatin A-4 analogues as potent antitumor agents.
Zhou P; Liang Y; Zhang H; Jiang H; Feng K; Xu P; Wang J; Wang X; Ding K; Luo C; Liu M; Wang Y
Eur J Med Chem; 2018 Jan; 144():817-842. PubMed ID: 29306206
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents.
Penthala NR; Zong H; Ketkar A; Madadi NR; Janganati V; Eoff RL; Guzman ML; Crooks PA
Eur J Med Chem; 2015 Mar; 92():212-20. PubMed ID: 25557492
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of Combretastatin-A4 Carboxamidest that Mimic Sulfonyl Piperazines by a Molecular Hybridization Approach: in vitro Cytotoxicity Evaluation and Inhibition of Tubulin Polymerization.
Jadala C; Sathish M; Anchi P; Tokala R; Lakshmi UJ; Reddy VG; Shankaraiah N; Godugu C; Kamal A
ChemMedChem; 2019 Dec; 14(24):2052-2060. PubMed ID: 31674147
[TBL] [Abstract][Full Text] [Related]
18. Structure-based discovery of a boronic acid bioisostere of combretastatin A-4.
Kong Y; Grembecka J; Edler MC; Hamel E; Mooberry SL; Sabat M; Rieger J; Brown ML
Chem Biol; 2005 Sep; 12(9):1007-14. PubMed ID: 16183025
[TBL] [Abstract][Full Text] [Related]
19. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41.
Pettit GR; Rhodes MR; Herald DL; Hamel E; Schmidt JM; Pettit RK
J Med Chem; 2005 Jun; 48(12):4087-99. PubMed ID: 15943482
[TBL] [Abstract][Full Text] [Related]
20. Novel HDAC/Tubulin Dual Inhibitor: Design, Synthesis and Docking Studies of α-Phthalimido-Chalcone Hybrids as Potential Anticancer Agents with Apoptosis-Inducing Activity.
Mourad AAE; Mourad MAE; Jones PG
Drug Des Devel Ther; 2020; 14():3111-3130. PubMed ID: 32848361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
